tHIS ASEAN 2025 to Debut in Kuala Lumpur, Uniting Southeast Asia's Healthcare Powerhouses
KUALA LUMPUR, Malaysia, May 29, 2025 /PRNewswire/ -- The Health Industry Series - ASEAN (tHIS ASEAN 2025), a groundbreaking event aimed at integrating healthcare resources across Southeast Asia, is set to take place in Kuala Lumpur during June 9-11. Co-located with the APHM International Healthcare Conference & Exhibition 2025, hosted by the Association of Private Hospitals of Malaysia (APHM), the events together will bring together over 5,000 professionals from the region's medical and healthcare sectors.
Spanning over 5,000 square meters, tHIS ASEAN 2025 will feature more than 200 Chinese enterprises showcasing their latest healthcare innovations, products, and technologies. The event is expected to attract government officials, hospital procurement leaders, distributors, and agents from across ASEAN.
Malaysia's Strategic Role in ASEAN Healthcare
As one of ASEAN's most dynamic economies, Malaysia is rapidly increasing investment in healthcare infrastructure and services. The government's ongoing reforms and commitment to medical innovation have made it a strategic hub for global health collaboration. The launch of tHIS ASEAN reflects a deepening cooperation between China and ASEAN nations, fostering regional integration in healthcare technology, products, and services.
Diverse Exhibition Zones and Strategic Partnerships
Held in strategic partnership with APHM and its network of over 200 exhibitors, the event will benefit from shared audiences and enhanced industry reach. tHIS ASEAN will highlight five core sectors: medical devices, rehabilitation and elderly care, pharmaceuticals, hospital construction, and the medical component manufacturing and design. These zones will comprehensively showcase the depth and breadth of China's healthcare capabilities and their applications in Southeast Asian markets.
Thought-Leadership Forums and Insightful Dialogues
tHIS ASEAN 2025 will also host a series of high-level forums covering a wide range of topics, including:
Confirmed speakers include:
To meet the diverse needs of attendees seeking targeted business opportunities, the event will feature a range of tailored services designed to enhance efficiency and foster meaningful connections. These include personalized one-on-one business matchmaking sessions, exclusive site visits to leading private hospitals, and curated networking activities — all designed to enhance efficiency, spark collaboration, and foster meaningful industry exchange. tHIS ASEAN aims to become the premier healthcare industry platform in Southeast Asia, driving forward healthcare innovation, service upgrades, and cross-border business cooperation. It marks a significant step toward a more integrated and innovative regional healthcare landscape.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
14 hours ago
- Korea Herald
Ph fintech GCash gives Filipinos free access to insurance through "Buy Load" service
MANILA, Philippines, June 4, 2025 /PRNewswire/ -- In line with the Philippines' efforts to further boost the local insurance industry, GCash, the Philippines' leading finance super app, introduces a new feature to unlock access to insurance for millions of Filipinos. The e-wallet is providing free health insurance, underwritten by FPG Insurance, when eligible users buy prepaid credits for themselves using the app's Buy Load service, empowering users to prepare for unexpected medical or hospitalization expenses. "This initiative, powered by our insurance platform, GInsure, in partnership with FPG Insurance, reflects our commitment to making financial protection accessible to every Filipino, ensuring that even the simplest transactions, like buying load, come with the added security of health coverage at no extra cost," said Winsley Bangit, VP and Group Head of New Businesses at GCash. The country's insurance penetration has grown in recent years, but it remains below 2%. With millions of Buy Load users on the app, GCash sees an opportunity to protect more Filipinos, offering an incentive beyond telecommunication services. "This benefit ensures users have funds for medical costs or can compensate for lost income during recovery, helping prevent families from falling into debt and alleviating financial struggles," Ren-Ren Reyes, president and CEO of GCash mobile wallet operator G-Xchange, Inc. The free health and accident insurance gives eligible users up to PHP 30,000 coverage and additional benefits. Users can also get income assistance when hospitalized due to illnesses and accidents, allowing them to receive PHP 500 per day salary assistance for a maximum of 5 days. They can also get up to PHP 10,000 disablement benefit, providing the user or their beneficiaries a safety net.
Korea Herald
3 days ago
- Korea Herald
International Healthcare Week 2025 - Innovate, Collaborate, And Elevate Healthcare In ASEAN And Beyond
KUALA LUMPUR, Malaysia, June 2, 2025 /PRNewswire/ -- International Healthcare Week (IHW) 2025, Southeast Asia's premier healthcare event, will be held from July 16 to 18 at the Malaysia International Trade and Exhibition Centre (MITEC), Kuala Lumpur. Organised by Informa Markets, IHW 2025 is set to be a transformative platform that accelerates healthcare innovation, fosters regional collaboration, and drives economic growth throughout the healthcare sector. With over 900 leading local, regional, and international exhibitors showcasing more than 15,000 products and services, and an expected attendance of 21,000 professionals from over 50 countries, IHW 2025 offers unmatched opportunities for networking, knowledge exchange, and business development. One Venue, Five Healthcare Trade Sh ows, One Unmissable Event IHW 2025 integrates five flagship international trade exhibitions under one roof, covering the entire healthcare value chain and enhancing opportunities to learn, collaborate, invest, and showcase innovations across healthcare sectors, noted Rungphech (Rose) Chitanuwat, Regional Portfolio Director – ASEAN at Informa Markets. Each exhibition is complemented by dedicated conferences tailored to the specific needs and developments of their respective industries: "Participants at IHW 2025 will have the unique advantage of exploring multiple healthcare sectors and attending 125 conference sessions tailored to diverse healthcare domains - all within a single venue. This integrated format eliminates the need to travel between separate events, allowing attendees to maximise their time and resources while gaining a comprehensive understanding of the latest market trends, innovative technologies, and cutting-edge solutions," said Rungphech. Malaysia – Leading the Way in Healthcare "Malaysia's robust healthcare market expansion, flourishing medical tourism sector, strategic regional location, supportive government initiatives, and ongoing advancements in healthcare infrastructure collectively establish the country as an ideal host for IHW 2025. This event will further cement Malaysia's status as a premier healthcare hub in ASEAN and serve as a gateway for global healthcare collaboration," highlighted Rungphech. As ASEAN Chair in 2025, Malaysia plays a pivotal role in promoting regional healthcare cooperation, addressing critical challenges such as supply chain resilience, digital health adoption, and sustainable health financing through platforms like the EU-ASEAN Health Summit. Strengthening Regional Healthcare Cooperation IHW 2025 is fully aligned with ASEAN's strategic objectives to bolster healthcare systems, enhance health outcomes, and promote equitable access across member states. The event serves as a vital platform for fostering networking and partnerships essential for advancing cross-border collaboration, policy harmonization, and increased investment in healthcare infrastructure and services. This collaborative environment supports key regional initiatives including digital health integration, combating non-communicable diseases, and pandemic preparedness-priorities underscored by recent public health challenges in Southeast Asia. MATRADE: A Strong and Strategic Partner As a valued partner of International Healthcare Week 2025, the Malaysia External Trade Development Corporation (MATRADE), Malaysia's national trade promotion agency, plays a crucial role in enhancing Malaysia's global visibility and reputation in the healthcare sector. Through promotion and fostering international collaborations, MATRADE actively positions Malaysia as a regional medical hub for Southeast Asia and beyond. YB Dato' Seri Reezal Merican Naina Merican, Chairman of MATRADE, emphasized the significance of IHW 2025, stating, "International Healthcare Week serves as a powerful platform that elevates Malaysia's standing as a regional leader in healthcare and medical services. This leading event not only promotes innovation but also directly contributes to our nation's economic growth by attracting world-class exhibitors, regional and international delegates, and top healthcare experts to Malaysia—fueling trade, knowledge sharing, and industry advancement." Join Us at IHW 2025 Healthcare professionals are invited to register online at to secure their place at this free-to-attend event. Don't miss this exceptional opportunity to contribute to shaping the future of the vibrant and evolving healthcare industry in ASEAN and beyond! About Informa Markets Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. We provide marketplace participants around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, targeted digital services and actionable data solutions. We connect buyers and sellers across more than a dozen global verticals, including Pharmaceuticals, Boating, Food, Fashion, and Infrastructure. As the world's leading market-making company, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year.
Korea Herald
3 days ago
- Korea Herald
J INTS BIO to Present Global Clinical Results from JIN-A02, a Fourth-Generation EGFR-TKI, at ASCO 2025
Significant anti-tumor responses and reduction of brain metastases observed SEOUL, South Korea , June 2, 2025 /PRNewswire/ -- J INTS BIO, a company specializing in the development of therapeutics for cancer and rare diseases, officially announced interim results from the global Phase 1/2 clinical trial of JIN-A02, its fourth-generation EGFR-TKI drug candidate, at the American Society of Clinical Oncology 2025 (ASCO 2025), the world's largest oncology conference, held in Chicago, USA. JIN-A02 is an oral, fourth-generation EGFR-TKI designed to overcome resistance mutations (such as C797S) that develop after treatment failure with third-generation EGFR-TKIs, which are currently the first-line therapy for EGFR-mutant Non-small cell lung cancer (NSCLC). It is currently undergoing clinical trials in South Korea, the United States, Thailand, and other countries. Key efficacy and safety results from Part A (dose escalation) of the multi-center clinical trial (NCT05394831) were presented. 'Confirmed' clinical response observed in patients with disease progression after 3 rd Generation EGFR TKI and chemotherapy One of the key findings of the ASCO presentation was that tumor responses were sustained in specific dose cohorts, with confirmed partial responses (PRs) verified by independent evaluation. Confirmed PRs were observed in 50mg,100mg and 300mg QD dose groups, providing clinical evidence of anti-tumor activity. In the 50 mg dose group, patients achieved a 77.3% reduction in tumor size, maintaining a PR over six consecutive treatment cycles (from cycle 3 to cycle 13). In the 300 mg dose group, a confirmed PR was observed with a 39.7% tumor size reduction, including a significant reduction in brain metastatic lesions. In the 100 mg dose group, a PR was also reported with a 35.3% reduction in tumor size, and brain metastatic lesions remained stable, further supporting the potential of JIN-A02 in treating brain metastases. Safety confirmed up to 300 mg, with therapeutic signals in brain metastases No dose-limiting toxicities (DLTs) or serious adverse events were observed with JIN-A02 at doses up to 300mg, which is six times the dose level when PR was first observed, demonstrating a favorable safety profile even at higher dose levels. The majority of adverse events reported at 300mg were mild (Grade 1-2) and included for the first time, Grade 1 skin rash, diarrhea, and skin desquamation in 3 out of 5 subjects – events commonly associated with EGFR inhibitors and generally considered clinically manageable. Importantly, there were no reports of systemic toxicities such as cardiovascular events or hepatotoxicity, supporting the drug's excellent safety profile. This safety and tolerability have translated into extended treatment durations in real-world settings, with a patient still on JIN-A02 after one year and seven months. In addition, the trial demonstrated notable responses in brain metastases first noted at 100mg, suggesting that JIN-A02 achieves therapeutically relevant concentrations in brain tissue. JIN-A02 gains national spotlight as government grants accelerate development In addition to the ASCO announcement, J INTS BIO continues to achieve noteworthy results in Korea. Recently, it was selected for the '2025 Baby Unicorn Fostering Project' by the Ministry of SMEs and Startups, officially recognizing both our scientific technology and commercialization potential. The 'Baby Unicorn Fostering Project' is a government project that focuses on developing promising startups with innovative technologies and growth potential in the global market as 'potential unicorns'. Companies selected for this project will receive full government support in recognition of their technological prowess and growth potential. With these accolades, JIN-A02 will receive dual funding for its Phase 2 trial and global expansion over the next two years, which is expected to be a decisive point to significantly accelerate the pace of clinical and commercialization in parallel with private investment. It is also significant as a case of securing confidence in the 3 arena of technology, marketability, and global scalability, as the recognition came from different government departments. Based on these achievements, we plan to initiate the Phase 2 clinical trial of JIN-A02 in before the end of this year, in discussions with the US FDA. "The ASCO presentation of JIN-A02's ability to induce anti-cancer responses and its ability to respond to central nervous system metastatic lesions is of great significance," said Dr. Anna Jo, CEO. "The government's continued support is a recognition of our technical capabilities and potential for growth. We will take advantage of this opportunity to accelerate global clinical expansion, technology transfer, and indication expansion to realize our goal of early commercialization"
